“Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)”

The Johnson and Johnson iMerge trial testing Geron’s Imetelstat for Myelodysplastic Syndrom was updated today (see https://clinicaltrials.gov/ct2/show/study/NCT02598661; obtained on 5-3-18). The author owns shares of…

Read more